Key result
In patients with cancer-associated venous thromboembolism, DOAC use was associated with a higher cumulative incidence of major bleeding compared to parenteral anticoagulants (3.9% vs 3.2%; P=0.01).
Why the study?
The study investigated real-world treatment patterns and bleeding complication rates in patients with cancer-associated venous thromboembolism.
Does DOAC treatment increase bleeding complications compared to parenteral anticoagulants or warfarin in patients with cancer-associated venous thromboembolism?
Population
27,205 CT and 57,711 non-CT patients with venous thromboembolism in Korea
Comparison
DOAC vs PAC vs warfarin vs mixed anticoagulants
Design
Population-based database study
Authors
Loading...
May warrant caution selecting DOACs for cancer-associated VTE; leaves open need for randomized confirmation.
Cohort (n=84,916)
Yes
Does DOAC treatment increase bleeding complications compared to parenteral anticoagulants or warfarin in patients with cancer-associated venous thromboembolism?
Absolute Event Rate: 3.9% vs 3.2%
p-value: p=0.01
In a Korean population-based cohort, DOACs were the most frequently used anticoagulants for cancer-associated VTE but were associated with higher bleeding rates compared to parenteral anticoagulants.
Kim et al. (2022) conducted a cohort in Cancer-associated venous thromboembolism (n=84,916). Direct oral anticoagulants (DOAC) vs. Parenteral anticoagulants (PAC) was evaluated on Major bleeding (p=0.01). In patients with cancer-associated venous thromboembolism, DOAC use was associated with a higher cumulative incidence of major bleeding compared to parenteral anticoagulants (3.9% vs 3.2%; P=0.01).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: